Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia
Search for other papers by Alice S. Mims in
Current site
Google Scholar
PubMed
For patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive induction regimens, all therapies include anthracycline- and cytarabine-based backbones. Core-binding factor AML is typically treated with gemtuzumab ozogamicin and 7 + 3 chemotherapy. Patients with FLT3-mutated (ITD or TKD) disease should have midostaurin + 7 + 3 and consolidation, and those with secondary or therapy-related AML should be considered for CPX-351. For patients ineligible for intensive induction regimens, venetoclax has changed the game and should be used in combination with hypomethylating agents or cytarabine. Glasdegib is also approved in combination with low-dose cytarabine. Patients with IDH1/2-mutated disease can be treated with ivosidenib and enasidenib, respectively. Although enasidenib has yet to secure its spot in the up-front setting, data support its use in newly diagnosed AML. An ongoing question in the field concerns how to treat patients with TP53-mutated AML, because most patients do not respond well to currently available therapies and continue to have poor overall outcomes.
Disclosures: Dr. Mims has disclosed receiving consulting fees from AbbVie, Inc., Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Daiichi- Sankyo Co., Genentech, Inc., Jazz Pharmaceuticals Inc., Kura Oncology, Inc., and Syndax.
© 2019-2023 National Comprehensive Cancer Network